Venture Talks#17 Marco Prunotto

Transforming Science into a Biotech

Despite billions of dollars supporting translational research, yet much of the work done in academic labs lacks the context, perspective, or results needed to attract private investment and enable the creation of new companies.

Marco Prunoto will be touching on a potential framework for academic scientists for conducting value-defining experiments for translation of research projects into investment-ready NewCos.

Who

Entrepreneurs or anyone with a startup idea.

When

Thursday 15 October 2026
12:15-13:15

Where

SIP, Building G
3rd floor, room 3H8

Rue des Vieux-Grenadiers
1205 Genève

Further Information

Marco Prunotto is a Venture Partner at Medicxi. Prior to joining Medicxi, Marco was Global Head of Technology and translational research at Roche Pharma I20 development where he was part of the leadership team. He previously served as Head of Translational Research at Galapagos NV. Prior to that he served in several roles within the discovery organisation of Roche pRED in Basel. He created and led the phenotypic drug discovery unit and led the nephrology discovery team. Marco received a PhD in Biotechnology from the University of Turin and conducted postdoctoral research at the University of Geneva. Marco also serves as senior lecturer at the School of Pharmaceutical Sciences of the University of Geneva.

More information about Medicxi

Events